Swiss generics and biosimilars drugmaker Sandoz today presented its net-sales performance for the nine months and third ...

US biotech Biogen (Nasdaq: BIIB) reported third-quarter 2025 revenue of $2.5 billion, up 3%, with GAAP diluted EPS of $3.17, ...

Swiss pharma giant Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic ...

Austrian biotech VALANX Biotech has appointed Klaus Orlinger as chief scientific officer, reinforcing its leadership as the ...

Danish pharma major Novo Nordisk today confirmed that it submitted an unsolicited proposal to acquire Metsera, aiming to ...

Swiss drug developer Oculis Holding today announced the pricing of offerings of an aggregate of 5,432,098 of its ordinary ...

South Korea-based Samsung Life Science Fund, created jointly between Samsung Biologics, Samsung Bioepis, and Samsung C&T , ...

The Institute for Clinical and Economic Review (ICER) has updated its assessment of the value of Novo Nordisk’s (NOV: N) ...

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) has entered a license and collaboration deal with OPKO Health’s (Nasdaq: ...

The Association for Accessible Medicines and its Council have welcomed a US regulator plan to simplify biosimilar approvals.

Bristol Myers Squibb (NYSE: BMY) reported third-quarter 2025 revenue of $12.2 billion, up 3% year-on-year, with non-GAAP earnings per share of $1.63. Growth was driven by the company’s newer products, ...

If the UK is to become Europe’s leading life sciences economy by 2030, it must sharpen its global appeal and do more to ...